A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double Blind, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab Versus Placebo for the Prevention of Persistent Posttraumatic Headache (PPTH)
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2018
At a glance
- Drugs Fremanezumab (Primary)
- Indications Post-traumatic headache
- Focus Proof of concept; Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 20 Dec 2018 Planned End Date changed from 12 Dec 2019 to 11 Dec 2019.
- 20 Dec 2018 Planned primary completion date changed from 12 Dec 2019 to 11 Dec 2019.
- 18 Oct 2018 Planned End Date changed from 7 Apr 2019 to 12 Dec 2019.